Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

The prognostic significance of cytokine receptor-like factor 2 expression and JAK2 mutation in pediatric B-cell acute lymphoblastic leukemia: A prospective cohort study

Полный текст:


Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Philadelphia (Ph)-like B-cell acute lymphoblastic leukemia (B-ALL) is defined by a gene expression profile similar to Phpositive B-ALL and shows a large number of genetic alterations in the cytokine receptor and kinasesignaling pathway genes that contribute to its aggressive phenotype and frequent disease recurrence – the main cause of death in affected children. Here, we aimed to correlate CRLF2 expression and JAK2 mutations in B-ALL patients with other prognostic factors and the patients’ outcomes as well as to evaluate their prognostic significance. The study was approved by the local institutional review board and written consents were obtained from a parent of each child before their enrolment. We included 54 newly diagnosed B-ALL pediatric patients (median age: 9.0 (2.0–18.0)) who were stratified either into a standard-risk (SR) or high-risk (HR) group and treated according to the modified BerlinFrankfurt-Münster 90 protocol (ALL-BFM 90). Fresh bone marrow samples were used to determine CRLF2 expression as well as to search for the JAK2 V617F mutation. Normal CRLF2 expression was reported in the SR patients much more often than in the HR group, while its overexpression was more common in the HR patients than in the SR ones (22 vs 6 and 18 vs 8, respectively, p < 0.001). CRLF2 was also more often overexpressed in the MRD-positive cases than in the negative ones (17 vs 9, p < 0.001), while normal CRLF2 expression was more common in the MRD-negative patients compared to the MRD-positive ones (24 vs 4, p < 0.001) which supports the unfavorable prognostic value of CRLF2 in relation to MRD positivity at the end of the induction treatment. JAK2 mutation was detected only in 2 patients belonging to the CRLF2 overexpression group which made the assessment of the prognostic significance of this mutation impossible. Notably, none of the patients with normal CRLF2 expression ended up relapsing while 4 patients with overexpressed CRLF2 developed a relapse (p = 0.031). The study subjects were followed up for up to 24 months, and we did not find CRLF2 overexpression to negatively influence overall survival, however, it did have an adverse effect on relapse-free survival. In summary, CRLF2 overexpression was found to be an unfavorable prognostic factor in childhood ALL as it was expressed more in high-risk patients and in those with poor treatment response. The analysis of CRLF2 expression in B-ALL pediatric patients may help in risk stratification and can potentially offer new treatment options based on novel CRLF2 inhibitors.

Об авторах

М. Abd El Monem
Mansoura University

R. El Ashry
Mansoura University

М. R. Bassiouny
Mansoura University

S. Aref
Mansoura University

S. Abd El Mabood
Mansoura University

Suzy Abd El Mabood, Associate Professor of Pediatrics, Pediatric Hematology, Oncology and BMT Unit, Mansoura University Children Hospital, Oncology Center Mansoura University, Faculty of Medicine

Elgomhouria St., 35516 Mansoura City, Egypt

Список литературы

1. Maloney KW, Devidas M, Wang C, Mattano L A, Friedmann A M, Buckley P et al. Outcome in children with standard-risk B cell acute lymphoblastic leukemia: results of Children's Oncology Group Trial AALL0331. J Clin Oncol. 2020;38(6):602- 12.

2. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H , Bont E D , et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34(22):2591-601

3. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5): 579-87

4. Germano, G., Del Giudice, L., Palatron, S., Giarin, E., Cazzaniga, G., Biondi, A. et al. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia 2003;17(8), 1573-82.

5. Harvey, R. C., & Tasian, S. K. Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia. Blood advances 2020; 4(1), 218-28

6. Iacobucci, I., & Roberts, K. G. Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia. Genes 2021; 12(5), 687.

7. Jerchel, I. Signaling Pathways as Therapeutic Targets in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia 2018.

8. Lanzkowsky P. Leukemias. In: Lanzkowsky P eds. Manual of PediatricHematology and Oncology. 3rd ed. San Diego: AcademicPress; 2005. p. 411-8.

9. Smith M, Arthur D, Camitta B, Carroll A J, Crist W, Gaynon P et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14:18–24.

10. Dworzak M, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia: iBFM-flow standards for immunophenotyping of pediatric ALL. Cytometry B Clin Cytom, 94 (1) 2018; pp. 82-93.

11. Syeed N. JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies. Asian Pac J Cancer Prev. 2019; 20(12): 3611–5.

12. Schrappe M, Reiter A, Sauter S, Ludwig WD, Wörmann B, Harbott J, et al. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents/ the significance of initial therapy response in blood and bone marrow]. KlinPadiatr. 1994;206:208-21.

13. Campana D. Molecular determinants of treatment response in acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program). 2008In press

14. World Medical Association. "World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects." Bulletin of the World Health Organization 2001; 79 (4): 373- 4.

15. Pui CH, Pei D, Coustan-Smith, E, Jeha S, Cheng C, Bowman W P, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. The lancet oncology 2015; 16(4), 465-74.

16. Chiaretti S, Brugnoletti F, Messina M, Paoloni F, Fedullo A L, Piciocchi, A et al. CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leukemia research 2016; 41, 36-42

17. Yamashita Y, Shimada A, Yamada T, Yamaji K, Hori T, Tsurusawa M, et al. IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013 Oct; 60(10):1587-92.

18. Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children’s Oncology Group study. Blood 2012; 119:3512–22.

19. Yano M, Imamura T, Asai D, Moriya-Saito A, Suenobu S, Hasegawa D, et al. An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression. Genes Chromosomes Cancer 2014; 53:815–82.

20. Cario G, Stanulla, M, Fine B M, Teuffel O, Neuhoff N V, Schrauder A, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005;105(2), 821-6.

21. Harvey R C, Mullighan C G, Wang X, Dobbin K K, Davidson G S, Bedrick, E. J et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood, The Journal of the American Society of Hematology 2010; 116(23), 4874-84.

22. Palmi C, Vendramini E, Silvestri D, Longinotti G, Frison D, Cario G, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia. 2012 Oct;26(10):2245-53.

23. Asai D, Imamura T, Suenobu S, Saito A, Hasegawa D, Deguchi T et al. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan Cancer Med. 2013 Jun;2(3):412-9.

24. Konoplev S, Lu X, Konopleva M, Jain N, Ouyang J, Goswami M, Roberts KG, et al. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience. Am J Clin Pathol. 2017 Apr 1;147(4):357-63.

25. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012; 22:153-66.

26. Roberts KG, Li Y, Payne-Turner D, Harvey R C, Li Yang Y, Pei D et al. Targetable kinase activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371:1005-15

27. Chen, X., & Wood, B. L. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. Blood reviews 2017; 31(2), 63-75.

28. Dou H , Chen X , Huang Y , Su Y , Lu L , Yu J , et al. Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2017 Feb;56(2):135-46.

Дополнительные файлы


Для цитирования:

Abd El Monem М., El Ashry R., Bassiouny М.R., Aref S., Abd El Mabood S. The prognostic significance of cytokine receptor-like factor 2 expression and JAK2 mutation in pediatric B-cell acute lymphoblastic leukemia: A prospective cohort study. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2023;22(1):40-45.

For citation:

Abd El Monem M., El Ashry R., Bassiouny M.R., Aref S., Abd El Mabood S. The prognostic significance of cytokine receptor-like factor 2 expression and JAK2 mutation in pediatric B-cell acute lymphoblastic leukemia: A prospective cohort study. Pediatric Hematology/Oncology and Immunopathology. 2023;22(1):40-45.

Просмотров: 144

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)